Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-3921 in adults with HTLV-1-associated myelopathy
jRCT2031210616Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of unasnemab in HTLV-1-associated myelopathy (HAM) (2 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Percentage of subjects with adverse events, Percentage of subjects with adverse reactions and 2 more. Started May 2022; status: completed.
02
Drugs
unasnemab
03
Conditions
HTLV-1-associated myelopathy (HAM)
Beyond the preview
Go deeper on jRCT2031210616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210616.